latest news releases from the newsroom
Dobson Communications Corporation
Dobson Communications Announces Proposed Debt Offering
OKLAHOMA CITY, Sept. 8, 2003 (PRIMEZONE) -- Dobson Communications Corporation (Nasdaq:DCEL) today announced the commencement of a private offering of $600 million principal amount of its Senior Notes due 2013. The proceeds from this offering, together with borrowings under a new $700 million senior credit facility that Dobson is currently arranging, will be used:
Dobson Communications Corporation
Dobson Communications and Dobson/Sygnet Commence Cash Tender Offers for Preferred Stock and Senior Notes
OKLAHOMA CITY, Sept. 8, 2003 (PRIMEZONE) -- Dobson Communications Corporation (Nasdaq:DCEL) today announced that it has commenced a cash tender offer (the "Dobson Offer") for up to 250,000 shares of its 12 1/4% Senior Exchangeable Preferred Stock (the "Shares"). The Dobson Offer is being made pursuant to an Offer to Purchase, dated September 8, 2003. The scheduled expiration date for the Dobson Offer is 5:00 p.m., New York City time, on October 7, 2003, unless extended. The consideration offered is an amount, paid in cash, equal to $1,061.25 per share, plus accrued and unpaid dividends to, but not including, the settlement date, payable on the settlement date.
Change to class action lawsuit against American Skandia turned down
STOCKHOLM, Sweden, Sept. 8, 2003 (PRIMEZONE) --Skandia (OtherOTC:SKNFF) (LSE:SDIAq): on 31 July 2003 Senior Judge Milton Pollack of the United States District Court for the Southern District of New York issued a decision and order in Donovan v. American Skandia Life Assurance Corp. et. al. dismissing the entire case with prejudice.
Q-Med receives FDA approval to initiate the ZUIDEX clinical trial in the USA
UPPSALA, Sweden, Sept. 8, 2003 (PRIMEZONE) -- Q-Med in Sweden has been informed by the FDA (Food and Drug Administration), the American regulatory authority, that the company's application to initiate clinical trials with ZUIDEX has been approved. Q- Med developed and markets ZUIDEX for the treatment of female stress urinary incontinence. The product has been marketed in Europe since September 2002. The main substance used in the ZUIDEX treatment is already approved by the FDA for use in children suffering from vesico- ureteral reflux (back-flow of urine).
Hannover Re named "Reinsurance Company of the Year"
Hannover, Germany, Sept. 08, 2003 (PRIMEZONE) -- Hannover Re has been named "Reinsurance Company of the Year 2003" by the highly respected UK trade journal "Reactions." Wilhelm Zeller, Chairman of the Executive Board, accepted the award yesterday at the annual Rendezvous de Septembre in Monte Carlo. The award is made on the basis of votes cast by the readers of "Reactions." They include not only insurers and reinsurers worldwide but also financial analysts, insurance and reinsurance brokers and rating agencies. The entire insurance and reinsurance sector as well as industry observers thus participated in the selection of our company. Accepting the award, Mr. Zeller commented: "We are proud of this distinction and we shall continue in future to do everything in our power to live up to this expression of confidence." Hannover Re was also named "Reinsurance Company of the Year" by the UK magazine "The Review" in the years 2001 and 1998.
IBS delivers supply chain solution for automotive spare parts chain
STOCKHOLM, Sweden, Sept. 08, 2003 (PRIMEZONE) -- IBS has signed an agreement with the MBD Group, owner of the Meca car parts chain, for the delivery of a new business system that will improve the efficiency of the customer's supply chain processes. The order is valued at SEK 12.8 million and covers software, services and hardware.
Tredje AP-fonden: AP3 appoints managers of European small and midcap equities
STOCKHOLM, Sweden, Sept. 08, 2003 (PRIMEZONE) -- The Third Swedish National Pension Fund (AP3) has appointed managers of European small and midcap equities. The total value of the mandate amounts to 291 million Euro. The mandate is divided between four asset managers, as follows: 117 million Euro to Axa Rosenberg Investment Management Ltd and 58 million Euro each to JP Morgan Fleming Asset Management (UK) Ltd, Kempen Capital Management (UK) Ltd and Pictet Asset Management UK Ltd. These managers have investment styles that complement each other well, contributing to the risk diversification of the portfolio. The reference index for the funded mandates is HSBC European Smaller Companies Index, ex Sweden.